Sanofi’s office building in Vitry-sur-Seine
Sanofi, the leading French pharmaceutical group, has confirmed that it will carry out layoffs in its global R&D division, including about 1,000 employees in France.
The French laboratory, Sanofi, announced last year that it would cut 1,700 jobs in Europe, including 1,000 in France, in line with the corporate strategy set by the group’s new boss, Paul Hudson.
Sanofi Laboratories France confirmed on Monday, January 18, that it will cut the number of employees employed by the group’s research and development (R&D) division. Olivier Bogillot, president of Sanofi France, noted to AFP: “This is in line with what we announced last June.” ; Previously, French news station France Inter reported that 400 jobs would be cut in this division.
President Boquillot further clarified, “In France, there will be about 1,000 employees leaving over a three-year period, in different units, including R&D. (…) We made this announcement last June, but it took time to deploy to develop all the strategic directions.”
Sanofi announced 1,700 job cuts in Europe last year, including 1,000 in France, corresponding to the strategy set by the group’s new boss, Paul Hudson.
Boquillot said, “We cannot comment on these figures precisely or say where the departures are taking place, because we must first provide this information to the bodies representing the staff.” He added, “But we have always indicated that this would be a voluntary separation program.” Negotiations are expected to begin at the end of January, and then in the second half of 2021, the first few batches of severance actions will begin to be implemented.
In total, Sanofi wants to cut “about 750 employees in R&D in Europe, including 400 positions in France and 350 in Germany,” according to the group’s Ms. Ethelric Eysseric. She said the dossier will probably be presented at the next central CSE agenda of the SARD, to be held on January 28.
Sanofi (Sanofi) Group announced at the end of 2019 that it wants to rationalize its spending with the goal of being able to save 2 billion euros by 2022, in particular by stopping the development of diabetes drugs, one of its traditional core R&D businesses, in addition to its Cardiovascular diseases division.
Recent Comments